secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2021-11-01T23:59:59+00:00
Accession:  0001193125-21-315574
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Therapeutics elects Ron Frieson as independent Class I director, effective Nov 1, 2021
--------------------------------------------------------------------------------

- Board expanded from 8 to 9 directors; Frieson's term expires at 2024 annual meeting.
- Frieson determined independent per Nasdaq rules; no related-party transactions.
- Entitled to annual cash retainer of $45,000, equity grants of 20,100 options and 13,700 RSUs.
- Received initial director grant: option for 80,200 shares at $3.13 (Nov 1 closing price).
- Standard indemnification agreement as per Company's non-employee director program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000119312521315574/0001193125-21-315574-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000119312521315574/d247159d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-315574

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer